According to cbdMD's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0148072. At the end of 2022 the company had a P/E ratio of -0.2315.
Year | P/E ratio | Change |
---|---|---|
2022 | -0.2315 | -86.28% |
2021 | -1.69 | -93.14% |
2020 | -24.6 | 3660.33% |
2019 | -0.6538 | -97.46% |
2018 | -25.8 | 118.18% |
2017 | -11.8 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.